Comparison With GLP-1 Monotherapy: Semaglutide 2.4 mg STEP-1 (semaglutide 2.4 mg, N=1,961) reported 14.9% mean weight loss at 68 weeks versus 2.4% placebo [6]
Indeed, other work has demonstrated that RT twice weekly has been shown to improve cognitive performance (Bolandzadeh et al., 2015), and taken alongside low-moderate intensity aerobic exercise such as walking (Lee et al., 2025), is likely to be well received by older adults - particularly if there is a social element integrated into the program (Dionigi, 2007)
A well-formulated peptide routine can help support skin that feels nourished while improving the appearance of texture and overall radiance
Why L-carnitine : endogenous synthesis decreases with age, needs increase (slower muscle recovery)
Tirzepatide and retatrutide have shown weight loss results comparable to bariatric surgery in clinical trials
Clinical Evidence: The STEP Program The STEP clinical trial program is the most relevant evidence base for semaglutide's weight management indication
)
